Phio Pharmaceuticals Corp (PHIO) Kapitalizatsiyaning foydaga nisbati

Phio Pharmaceuticals Corp. (PHIO) korporativ emblemasi va logotipi

Phio Pharmaceuticals melanoma bilan kurashish uchun noyob INTASYL tizimini ishlab chiqqan holda va immun hujayralarini modifikatsiya qilishga investitsiya kiritgan holda RNA terapiyasi sohasida yetakchilik qilmoqda. GURU.Markets platformasidagi ushbu narxlar grafigi, unda ko'rsatkich -0.70 darajasida turibdi, bozor baholovini tasdiqlovchi hujjat bo'lib xizmat qiladi va genetika hamda onkologiya mutaxassislari jamoasining tajribasiga tayangan. Ilmiy hamjamiyatning maqsadli aralashuv usullariga bo'lgan yuqori ishonchi brendning klinik sinovlari uchun barqaror qo'llab-quvvatlashni ta'minlaydi.

RXi Pharmaceuticals (PHIO) - Narxning foydaga nisbati 04.07.2022dan 13.11.2026gacha

Phio Pharmaceuticals Corp (PHIO) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- bozor qiymati va tahlilchilarning maqsadli prognozi:
Birja grafigi RXi Pharmaceuticals|PHIO - Maqsadli narxlar grafigi
- bozor kapitallashuvi tafsilotlari:
Bozor qiymati Phio Pharmaceuticals Corp.|PHIO - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- xususiy kapitalning balans qiymati ko'rsatkichlari:
Aksiyaning buxgalteriya qiymati Phio Pharmaceuticals|PHIO - Kompaniyaning balans qiymati|Sof aktivlarga nisbatan bozor kapitallashuvi phiopharma.com|PHIO - Kompaniyaning umumiy aktivlari
- qarz majburiyatlari va likvidlik statistikasi:
Barcha qarzlarning o‘z mablag‘lariga nisbati Phio Pharmaceuticals|PHIO - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati RXi Pharmaceuticals|PHIO - Kompaniya qarzlari|Qarzning sof aktivlarga nisbati Phio Pharmaceuticals Corp.|PHIO - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli majburiyatlari Phio Pharmaceuticals|Tezkor likvidlik koeffitsiyenti phiopharma.com
- foyda va baholash multiplikatorlari ko'rsatkichlari:
PHIO - Sof foyda|Kelajakdagi foyda Phio Pharmaceuticals|PHIO - P/E multiplikatori|Prognoz qilingan narx-foyda nisbati RXi Pharmaceuticals|PHIO - Narx-foyda va o‘sish multiplikatori|EV/EBITDA multiplikatori Phio Pharmaceuticals Corp.|PHIO - Eskirish chegirilmasdan oldingi operatsion foyda|So'nggi to'rtta chorak uchun bir aksiya uchun foyda Phio Pharmaceuticals|PHIO - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik o'zgarishi phiopharma.com|PHIO - Joriy yilda foyda o'sishi|Keyingi yil uchun bir aksiya uchun kutilayotgan foyda o'sishi Phio Pharmaceuticals
Kompaniyaning har tomonlama tahlili:phiopharma.com - PHIO
Phio Pharmaceuticals Corp yetakchi tovari

P/E koeffitsiyenti sof daromadning bir birligining bozor qiymatini o'lchab, investitsiyalarning qoplanish muddatini va bozorning kelajakdagi pul oqimlariga bo'lgan ishonchini belgilaydi. Sof daromadga asoslangan P/E koeffitsiyentini tahlil qilish orqali investor Phio Pharmaceuticals (PHIO) kompaniyasining yetakchi genetiklarni saqlab qolish va DNK tahlili AI platformalariga sarflagan xarajatlari uzoq muddatli istiqbolda joriy kapitalizatsiya bilan oqlangan yoki oqlanmaganini baholaydi.

Raqobatdosh kompaniyalar tahlili

Tempus AI Inc (TEM) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Qiagen (QGEN)|IONS - Kapitalizatsiyaning foydaga nisbati|Repligen Corp. - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati RNA|CRSP - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati WGS|RARE: P/E multiplikatori|Beam Therapeutics Inc - Kompaniya qiymatining sof foydaga nisbati|SRPT (Sarepta Therapeutics Inc) - P/E multiplikatori|P/E multiplikatori Twist Bioscience Corp|Narxning foydaga nisbati 10x Genomics, Inc. (TXG)|NTLA (intelliatx.com) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Stoke Therapeutics, Inc. STOK|BLFS - Narx-foyda koeffitsiyenti|Wave Life Sciences Corp - P/E multiplikatori|MAZE - P/E multiplikatori|SION: P/E multiplikatori|Narx-foyda koeffitsiyenti primemedicine.com|TSHA (Taysha Gene Therapies, Inc.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati uniQure NV QURE|Narx-foyda koeffitsiyenti MGTX (MeiraGTx PLC)|P/E multiplikatori REGENXBIO Corp (RGNX)|Solid Biosciences Inc. - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati OCGN (ocugen.com)|PacBio - P/E multiplikatori|Biznesning o‘zini qoplash muddati Benitec Biopharma Inc BNTC|DSGN: P/E multiplikatori|Narx-foyda koeffitsiyenti Rocket Corp|FDMT (4D Molecular Therapeutics) - P/E multiplikatori|P/E multiplikatori Lexeo|Narxning foydaga nisbati Korro Bio, Inc. (KRRO)|Narxning foydaga nisbati EDIT (Editas Medicine Inc)|Narxning foydaga nisbati Silence Therapeutics Inc. SLN|Biznesning o‘zini qoplash muddati ProQR (PRQR)|CDXS - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati SGMO|NAUT: P/E multiplikatori|Metagenomi Inc. - Kompaniya qiymatining sof foydaga nisbati|DTIL (Precision BioSciences, Inc.) - P/E multiplikatori|Generation Bio Corp (GBIO) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Boundless Bio, Inc. (BOLD)|XCUR - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori IMNN (Imunon)|MBIO: Narx-foyda multiplikatori|RNAZ - Narxning foydaga nisbati|BNGO (Bionano Genomics, Inc.) - Narx-foyda multiplikatori|APDN: P/E multiplikatori|bluebirdbio.com (BLUE) - P/E multiplikatori|Narxning foydaga nisbati ImmunoPrecise Antibodies Ltd|Omega Therapeutics Inc - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori OMIC|RGLS (Regulus) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori SYRS (Syros Pharmaceuticals)|Biznesning o‘zini qoplash muddati telesisbio.com (TBIO)|TCON - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Unity Biotechnology Inc.